Biohaven Pharmaceutical Holding Company Ltd

NYSE:BHVN   3:59:54 PM EDT
145.99
+0.68 (+0.47%)
Products

FDA Accepts For Review Biohaven's NDA Of Migraine Treatment

Published: 05/23/2022 11:47 GMT
Biohaven Pharmaceutical Holding Company Ltd (BHVN) - Us FDA Accepts for Review Biohaven's New Drug Application (nda) Filing of Intranasal Zavegepant for the Acute Treatment of Migraine.
Biohaven Pharmaceutical Holding Company Ltd - Prescription Drug User Fee Act (pdufa) Goal Date for Completion of FDA Review of NDA is Set for 1q2023.